ResMed Inc. (RMD): Price and Financial Metrics
ResMed Inc. (RMD)
Today's Latest Price: $183.03 USD
Updated Oct 23 6:40pm
Add RMD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
RMD Stock Summary
- RMD has a market capitalization of $25,956,054,151 -- more than approximately 92.16% of US stocks.
- Price to trailing twelve month operating cash flow for RMD is currently 32.35, higher than 87.94% of US stocks with positive operating cash flow.
- The volatility of Resmed Inc's share price is greater than that of only 7.05% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to RMD, based on their financial statements, market capitalization, and price volatility, are A, HOLX, LOGI, CERN, and VAR.
- Visit RMD's SEC page to see the company's official filings. To visit the company's web site, go to www.resmed.com.
RMD Stock Price Chart Interactive Chart >
RMD Price/Volume Stats
| Current price | $183.03 | 52-week high | $208.99 |
| Prev. close | $182.82 | 52-week low | $108.85 |
| Day low | $181.03 | Volume | 304,900 |
| Day high | $183.70 | Avg. volume | 674,251 |
| 50-day MA | $175.85 | Dividend yield | 0.85% |
| 200-day MA | $170.29 | Market Cap | 26.52B |
ResMed Inc. (RMD) Company Bio
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing. The company was founded in 1989 and is based in San Diego, California.
RMD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $183.03 | $73.68 | -60% |
We started the process of determining a valid price forecast for Resmed Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Resmed Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for RMD, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 19.16; that's higher than 85.51% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 14.6% of the free cash flow producing stocks we're observing.
- RMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 44.31% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -61% |
| 1% | -60% |
| 2% | -60% |
| 3% | -59% |
| 4% | -59% |
| 5% | -59% |
IONS, A, ENTA, XRAY, and PKI can be thought of as valuation peers to RMD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...